$NKTR

Nektar Therapeutics faces class action lawsuit alleging REZOLVE-AA trial protocol violations and misstatements, affecting investors from February-December 2025.

Nektar Therapeutics faces securities class action lawsuit alleging REZOLVE-AA trial enrolled four ineligible patients, masking disappointing efficacy results.

Class action lawsuit filed against $NKTR for allegedly concealing REZOLVE-AA trial protocol violations and ineligible patient enrollment. Stock fell 7.77% on trial failure announcement.

Nektar Therapeutics faces securities class action lawsuit alleging false statements about REZOLVE-AA trial. Lead plaintiff deadline set for May 5, 2026.

Rosen Law Firm files class actions against $RGC, $GLOB, $NKTR alleging false statements. Investors have until June 23, 2026 to become lead plaintiffs.

Class action lawsuit filed against $NKTR alleging materially false statements regarding REZOLVE-AA trial enrollment protocols, claiming significant negative impact on trial integrity and results.

Class action lawsuit filed against Nektar Therapeutics alleging false statements about REZOLVE-AA trial enrollment protocols. Investors harmed between February-December 2025 can join case.

Nektar Therapeutics faces securities fraud lawsuit over failed alopecia trial and alleged protocol disclosure violations. Stock fell 7.8% on December 16, 2025.

Nektar Therapeutics faces class action suit alleging REZOLVE-AA trial protocol violations. Investors urged to act by May 2026 deadline.

Rosen Law Firm urges Nektar investors to join securities class action alleging false statements about REZOLVE-AA trial enrollment. Deadline: May 5, 2026.

Pomerantz LLP filed class action against $NKTR over REZOLVE-AA trial failure. Stock dropped 7.77% after December disclosure of ineligible patient enrollment issues.

Eos Energy stock plummeted 39.44% after missing earnings targets due to production and quality control issues, prompting Pomerantz Law Firm to file securities fraud class action lawsuit.

Pomerantz Law Firm filed securities fraud lawsuit against $AQST after FDA rejected Anaphylm NDA, triggering 37% stock drop. Investor deadline May 4.

Pomerantz Law Firm files class action lawsuit against $CORT after FDA rejection of relacorilant causes 50.4% stock decline. Investors urged to act by April 21, 2026 deadline.

Nektar Therapeutics surges 18% after reporting positive phase 2b results for rezpegaldesleukin, an investigational alopecia areata treatment, advancing into later-stage trials.

Nektar Therapeutics faces securities class action over alleged REZOLVE-AA trial disclosure failures. Investors who purchased shares February-December 2025 may seek recovery; lead plaintiff deadline is May 5, 2026.

Class action lawsuit filed against $NKTR alleging false statements about REZOLVE-AA trial enrollment and integrity. Lead plaintiff deadline set for May 5, 2026.

Rosen Law Firm seeks lead plaintiffs in class action against $NKTR over alleged false statements regarding REZOLVE-AA trial enrollment. Deadline: May 5, 2026.

Four firms face securities fraud lawsuits alleging operational and financial misstatements. Lead plaintiff deadlines: May 5-8, 2026.

Rosen Law Firm alerts $NKTR investors of May 5, 2026 deadline to join securities class action over alleged false statements regarding REZOLVE-AA trial enrollment protocols.